Literature DB >> 6471891

Myocardial protection during prolonged aortic cross-clamping. Comparison of blood and crystalloid cardioplegia.

F P Catinella, J N Cunningham, F C Spencer.   

Abstract

We compared the ability of blood and crystalloid cardioplegia to protect the myocardium during prolonged arrest. Twelve dogs underwent 180 minutes of continuous arrest. Group I (six dogs) received 750 ml of blood cardioplegic solution (potassium chloride 30 mEq/L) initially and every 30 minutes. Group II (six dogs) received an identical amount of crystalloid cardioplegic solution (potassium chloride 30 mEq, methylprednisolone 1 gm, and 50% dextrose in water 16 ml/L of electrolyte solution). Temperature was 10 degrees C and pH 8.0 in both groups. Studies of myocardial biochemistry, physiology, and ultrastructure were completed before arrest and 30 minutes after normothermic reperfusion. Biopsy specimens for determination of adenosine triphosphate were obtained before, during, and after the arrest interval. Regional myocardial blood flow, total coronary blood flow, and myocardial oxygen consumption were statistically unchanged in Group I (p greater than 0.05). Total coronary blood flow rose 196% +/- 49% in Group II (p less than 0.005), and left ventricular endocardial/epicardial flow ratio fell significantly in this group from 1.51 +/- 0.18 to 0.8 +/- 0.09, p less than 0.01 (mean +/- standard error of the mean. The rise in myocardial oxygen consumption was not significant in this group (34% +/- 36%, p greater than 0.05). Ventricular function and compliance were statistically unchanged in both groups. In Group II, adenosine triphosphate fell 18% +/- 3.4% (p less than 0.005) after 30 minutes of reperfusion; it was unchanged in Group I. Ultrastructural appearance in both groups correlated with these changes. We conclude that blood cardioplegia offers several distinct advantages over crystalloid cardioplegia during prolonged arrest.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6471891

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  7 in total

1.  Whole blood cardioplegia (minicardioplegia) reduces myocardial edema after ischemic injury and cardiopulmonary bypass.

Authors:  Ulysses G McCann; Charles J Lutz; Anthony L Picone; Bruce Searles; Louis A Gatto; Karikehalli A Dilip; Gary F Nieman
Journal:  J Extra Corpor Technol       Date:  2006-03

2.  New insights on the use of del Nido cardioplegia in the adult cardiac surgery.

Authors:  Paolo Nardi; Calogera Pisano; Fabio Bertoldo; Giovanni Ruvolo
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

3.  [Intermittent warm blood cardioplegia--an experimental study].

Authors:  T Yamada
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-08

4.  Cold crystalloid versus warm blood cardioplegia in patients undergoing aortic valve replacement.

Authors:  Paolo Nardi; Sara R Vacirca; Marco Russo; Dionisio F Colella; Carlo Bassano; Antonio Scafuri; Antonio Pellegrino; Gerry Melino; Giovanni Ruvolo
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

5.  Is cold blood cardioplegia absolutely superior to cold crystalloid cardioplegia in aortic valve surgery?

Authors:  Daniel A Lerman; Matilde Otero-Losada; Kiddy Ume; Pablo A Salgado; Sai Prasad; Kelvin Lim; Bruno Péault; Nasri Alotti
Journal:  J Cardiovasc Surg (Torino)       Date:  2017-05-26       Impact factor: 1.888

6.  Clinical Results of Different Myocardial Protection Techniques in Aortic Stenosis.

Authors:  Jung Hee Lee; Dong Seop Jeong; Kiick Sung; Wook Sung Kim; Young Tak Lee; Pyo Won Park
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2015-06-05

7.  Custodiol HTK versus Plegisol: in-vitro comparison with the use of immature (H9C2) and mature (HCM) cardiomyocytes cultures.

Authors:  Rafał Nowicki; Mikołaj Berezowski; Julita Kulbacka; Katarzyna Bieżuńska-Kusiak; Marek Jasiński; Jolanta Saczko
Journal:  BMC Cardiovasc Disord       Date:  2022-03-17       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.